RSS   Newsletter   Contact   Advertise with us
Post Online Media
Post Online Media Magazine

Roche reports strong start in 2019 and raises outlook for full-year

Share on Twitter Share on LinkedIn
Christian Fernsby |
Roche
Roche   Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion

In the first three months of 2019, Roche sales rose 8% to CHF 14.8 billion.

Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion.

Key growth drivers were the multiple sclerosis medicine Ocrevus and cancer medicines Perjeta and Tecentriq as well as the new haemophilia medicine Hemlibra.

As expected, the strong uptake of newly introduced medicines was partially offset by lower sales of Herceptin and of MabThera/Rituxan.

In the US, sales increased 14%, led by Ocrevus, Hemlibra, Perjeta and Tecentriq.

Ocrevus sales were driven by both new and continuing patient demand.

In Europe (-6%), sales were affected by competition from biosimilars for Herceptin (-44%) and MabThera/Rituxan (-38%).

This decline was partially offset by the strong growth of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.

In the International region sales grew 17%, mainly driven by China.

In Japan, sales increased 7%, driven by recently launched products, including Tecentriq, Hemlibra and Perjeta.

This growth was partially offset by biosimilar competition for MabThera/Rituxan (-50%) and Herceptin (-9%).

Diagnostics Division sales increased 1% to CHF 2.9 billion.

Molecular Diagnostics (+7%) was the main contributor, led by the growth of its cervical cancer business.

In regional terms, growth was reported in EMEA2 (+3%) and Latin America (+8%).

Sales were impacted by one-time supply chain effects in Centralised and Point of Care Solutions in Asia-Pacific and in coagulation monitoring systems in North America.


What to read next
POST Online Media Contact